Recent News

• 02.11.2026 - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• 01.11.2026 - Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
• 01.05.2026 - Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference
• 12.19.2025 - Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
• 12.09.2025 - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• 11.21.2025 - Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
• 11.19.2025 - Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference
• 11.18.2025 - Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Recent Filings

• 01.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.20.2026 - 144 Report of proposed sale of securities
• 01.12.2026 - 8-K Current report
• 01.12.2026 - EX-99.1 EX-99.1
• 12.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.17.2025 - 144 Report of proposed sale of securities
• 12.17.2025 - 144 Report of proposed sale of securities
• 12.17.2025 - 144 Report of proposed sale of securities